title: Interferon alfa for macular degeneration.
abstract: Clinical studies demonstrate that interferon alfa has little benefit in treating CNV secondary to macular degeneration. However, it may be useful in the treatment of choroidal and retinal hemangiomas, diabetic and post-vein occlusion retinopathy, and retinopathy of prematurity.
authors.affiliation: Womack Army Medical Center, Ft Bragg, NC 28307, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Williford
authors.forename: T
authors.initials: T
authors.lastname: King
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D008268:Macular Degeneration / Q000188:drug therapy*; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins